MR
MREO.US Mereo BioPharma Group PLC ADR
- Market cap
- USD 48.7M
- P/E
- -
- P/B
- 2.07x
- ROE
- -110.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MREO.US undervalued?
Graham numberThe Graham number of Mereo BioPharma Group PLC ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mereo BioPharma Group PLC ADR fundamental analysis
No fundamental analysis for Mereo BioPharma Group PLC ADR yet.
Mereo BioPharma Group PLC ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autos…
Full company profileMereo BioPharma Group PLC ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mereo BioPharma Group PLC ADR annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | -3.29M | 0.00 | -122K | 393K | 36.5M | 1.51M | 10.0M | 0.00 | 500K | 1.07M |
| Gross Profit | -24.6M | -37.9M | -22.7M | -2.01M | -2.05M | 18.6M | 1.15M | 7.43M | -1.09M | 367K | 661K |
| Operating Income | -36.2M | -45.3M | -35.2M | -50.4M | -48.2M | -20.9M | -54.4M | -28.4M | -47.4M | -38.3M | -29.3M |
| EBITDA | -38.4M | -44.4M | -34.9M | -44.6M | -203M | 18.9M | -37.9M | -26.1M | 1.09M | -40.5M | -27.8M |
| Net Income | -28.4M | -38.8M | -32.0M | -44.5M | -210M | 12.7M | -42.2M | -29.5M | -43.3M | -41.9M | -26.1M |
| EPS | -0.63 | -2.81 | -2.25 | -2.49 | -3.10 | 0.11 | -1.85 | -0.22 | -1.46 | -0.26 | -0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 86.8M | 96.3M | 67.3M | 115M | 86.1M | 171M | 77.4M | 66.5M | 76.4M | 45.9M | 29.6M |
| Total Liabilities | 7.51M | 33.9M | 34.5M | 61.2M | 107M | 51.9M | 26.0M | 16.0M | 15.4M | 5.00M | 5.87M |
| Shareholders' Equity | 79.3M | 62.5M | 32.8M | 53.3M | -20.5M | 119M | 51.4M | 50.5M | 61.0M | 40.9M | 23.7M |
| Cash & Short-term Investments | 53.6M | 52.5M | 27.5M | 21.7M | 32.1M | 128M | 68.2M | 57.4M | 69.8M | 41.0M | 26.1M |
| Total Debt | 3.13M | 20.8M | 21.5M | 42.9M | 24.5M | 22.7M | 15.4M | 5.95M | 6.43M | 202K | 577K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.4M | -32.1M | -23.1M | -60.2M | -38.6M | -7.07M | -48.8M | -21.1M | -32.8M | -31.0M | -19.2M |
| Capital Expenditure | 3.47K | 2.30M | 35.5K | 27.5K | 21.8K | 722K | 13.0K | 419K | 699K | 20.0K | 799K |
| Free Cash Flow | -27.4M | -34.4M | -23.2M | -60.3M | -38.6M | -7.79M | -48.8M | -21.6M | -33.5M | -31.0M | -18.8M |
| Ratios | |||||||||||
| ROE | -35.8% | -62.1% | -97.7% | -83.4% | - | 10.7% | -82.1% | -58.3% | -70.9% | -102.4% | -110.1% |
| ROA | -32.7% | -40.3% | -47.6% | -38.8% | -243.8% | 7.4% | -54.5% | -44.3% | -56.6% | -91.2% | -88.2% |
| Net Profit Margin | - | - | - | - | -53,391.6% | 34.9% | -2,801.6% | -294.7% | - | -8,375.6% | -2,447.0% |
| Debt to Equity | 0.04x | 0.33x | 0.66x | 0.81x | - | 0.19x | 0.30x | 0.12x | 0.11x | 0.00x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mereo BioPharma Group PLC ADR dividends
Mereo BioPharma Group PLC ADR has not paid dividends in the last 9 fiscal years.
Who owns Mereo BioPharma Group PLC ADR
- Insiders 0.92%
- Institutions 33.64%
- Public & others 65.44%
- Shares outstanding 160M
- Free float 125M
Top funds holding MREO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| International Biotechnology Ord | 1.07M | 0.67% | 0.00% | Jul 2026 |
Top institutions holding MREO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Rubric Capital Management LP | 15.3M | 9.59% | 0.00% | Jun 2026 |
| Bank of America Corp | 8.20M | 5.13% | 0.00% | Jun 2026 |
| Defilade Capital Management, L.P. | 7.56M | 4.73% | 0.00% | Jun 2026 |
| Newtyn Management LLC | 3.00M | 1.88% | -57.62% | Jun 2026 |
| Tejara Capital Ltd | 2.01M | 1.26% | -1.13% | Sep 2026 |
| UBS Group AG | 1.45M | 0.91% | -2.85% | Jun 2026 |
| Two Sigma Investments LLC | 1.32M | 0.83% | +602.33% | Jun 2026 |
| EcoR1 Capital, LLC | 1.00M | 0.63% | -92.52% | Jun 2026 |
| Jane Street Group LLC | 775K | 0.49% | +453.64% | Jun 2026 |
| Ishara Investments LP | 769K | 0.48% | 0.00% | Jun 2026 |
| Sontag Advisory LLC | 765K | 0.48% | -3.90% | Jun 2026 |
| Citadel Advisors Llc | 444K | 0.28% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 213K | 0.13% | +8.86% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 180K | 0.11% | -73.82% | Jun 2026 |
| XTX Topco Ltd | 174K | 0.11% | +106.56% | Jun 2026 |
| Group One Trading, LLC | 168K | 0.10% | -50.12% | Jun 2026 |
| Renaissance Technologies Corp | 160K | 0.10% | +207.33% | Sep 2026 |
| State Street Corp | 135K | 0.08% | +1.04% | Jun 2026 |
| Significant Wealth Partners LLC | 129K | 0.08% | +296.12% | Sep 2026 |
| Nomura Holdings Inc | 104K | 0.07% | 0.00% | Jun 2026 |
Mereo BioPharma Group PLC ADR company profile
- Company name
- Mereo BioPharma Group PLC ADR
- Ticker
- MREO.US
- Exchange
- USA Stocks
- Listed since
- Apr 24, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Fiscal year end
- December
- Address
- One Cavendish Place, London, United Kingdom, W1G 0QF
- Phone
- 44 33 3023 7300
- Website
- mereobiopharma.com
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Mereo BioPharma Group PLC ADR management
9- Dr. Denise Vera Scots-Knight Ph.D.Co-Founder, CEO & Executive Director · born 1959
- Mr. Charles Edward SermonCo-Founder, General Counsel, Business Development & Company Secretary · born 1969
- Ms. Christine Fox CPAChief Financial Officer · born 1981
- Dr. John A. Lewicki Ph.D.Chief Scientific Officer · born 1952
- Ms. Bal LallyVP & Head of HR
- Dr. Jackie ParkinSenior VP & Therapeutic Head · born 1958
- Ms. Alexandra Hughes-WilsonChief of Patient Access & Commercial Planning · born 1971
- Mr. Bo KaraSenior VP and Head of Pharmaceutical Development & CMC
- Ms. Bharti NavsariwalaVP & Head of Regulatory Affairs